Literature DB >> 29169992

HAX-1 regulates SERCA2a oxidation and degradation.

Philip A Bidwell1, Guan-Sheng Liu1, Narayani Nagarajan2, Chi Keung Lam1, Kobra Haghighi1, George Gardner1, Wen-Feng Cai1, Wen Zhao1, Luke Mugge1, Elizabeth Vafiadaki3, Despina Sanoudou4, Jack Rubinstein5, Djamel Lebeche6, Roger Hajjar6, Junichi Sadoshima2, Evangelia G Kranias7.   

Abstract

Ischemia/reperfusion injury is associated with contractile dysfunction and increased cardiomyocyte death. Overexpression of the hematopoietic lineage substrate-1-associated protein X-1 (HAX-1) has been shown to protect from cellular injury but the function of endogenous HAX-1 remains obscure due to early lethality of the knockout mouse. Herein we generated a cardiac-specific and inducible HAX-1 deficient model, which uncovered an unexpected role of HAX-1 in regulation of sarco/endoplasmic reticulum Ca-ATPase (SERCA2a) in ischemia/reperfusion injury. Although ablation of HAX-1 in the adult heart elicited no morphological alterations under non-stress conditions, it diminished contractile recovery and increased infarct size upon ischemia/reperfusion injury. These detrimental effects were associated with increased loss of SERCA2a. Enhanced SERCA2a degradation was not due to alterations in calpain and calpastatin levels or calpain activity. Conversely, HAX-1 overexpression improved contractile recovery and maintained SERCA2a levels. The regulatory effects of HAX-1 on SERCA2a degradation were observed at multiple levels, including intact hearts, isolated cardiomyocytes and sarcoplasmic reticulum microsomes. Mechanistically, HAX-1 ablation elicited increased production of reactive oxygen species at the sarco/endoplasic reticulum compartment, resulting in SERCA2a oxidation and a predisposition to its proteolysis. This effect may be mediated by NAPDH oxidase 4 (NOX4), a novel binding partner of HAX-1. Accordingly, NOX inhibition with apocynin abrogated the effects of HAX-1 ablation in hearts subjected to ischemia/reperfusion injury. Taken together, our findings reveal a role of HAX-1 in the regulation of oxidative stress and SERCA2a degradation, implicating its importance in calcium homeostasis and cell survival pathways.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  HAX-1; Heart; Ischemia reperfusion; NOX4; Oxidative modification; Proteolysis; SERCA2a

Mesh:

Substances:

Year:  2017        PMID: 29169992      PMCID: PMC5801168          DOI: 10.1016/j.yjmcc.2017.11.014

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  56 in total

1.  Phospholamban interacts with HAX-1, a mitochondrial protein with anti-apoptotic function.

Authors:  Elizabeth Vafiadaki; Despina Sanoudou; Demetrios A Arvanitis; Dawn H Catino; Evangelia G Kranias; Aikaterini Kontrogianni-Konstantopoulos
Journal:  J Mol Biol       Date:  2006-10-21       Impact factor: 5.469

Review 2.  Modulation of signaling mechanisms in the heart by thioredoxin 1.

Authors:  Narayani Nagarajan; Shinichi Oka; Junichi Sadoshima
Journal:  Free Radic Biol Med       Date:  2016-12-16       Impact factor: 7.376

3.  NADPH oxidase 4 (Nox4) is a major source of oxidative stress in the failing heart.

Authors:  Junya Kuroda; Tetsuro Ago; Shouji Matsushima; Peiyong Zhai; Michael D Schneider; Junichi Sadoshima
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-16       Impact factor: 11.205

4.  Hax1-mediated processing of HtrA2 by Parl allows survival of lymphocytes and neurons.

Authors:  Jyh-Rong Chao; Evan Parganas; Kelli Boyd; Cheol Yi Hong; Joseph T Opferman; James N Ihle
Journal:  Nature       Date:  2008-02-20       Impact factor: 49.962

5.  The anti-apoptotic protein HAX-1 is a regulator of cardiac function.

Authors:  Wen Zhao; Jason R Waggoner; Zhi-Guo Zhang; Chi Keung Lam; Peidong Han; Jiang Qian; Paul M Schroder; Bryan Mitton; Aikaterini Kontrogianni-Konstantopoulos; Seth L Robia; Evangelia G Kranias
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-17       Impact factor: 11.205

6.  Novel role of HAX-1 in ischemic injury protection involvement of heat shock protein 90.

Authors:  Chi Keung Lam; Wen Zhao; Wenfeng Cai; Elizabeth Vafiadaki; Stela M Florea; Xiaoping Ren; Yong Liu; Nathan Robbins; Zhiguo Zhang; Xiaoyang Zhou; Min Jiang; Jack Rubinstein; W Keith Jones; Evangelia G Kranias
Journal:  Circ Res       Date:  2012-09-14       Impact factor: 17.367

7.  Epstein-Barr virus (EBV) nuclear antigen leader protein (EBNA-LP) forms complexes with a cellular anti-apoptosis protein Bcl-2 or its EBV counterpart BHRF1 through HS1-associated protein X-1.

Authors:  Go Matsuda; Kaori Nakajima; Yasushi Kawaguchi; Yuji Yamanashi; Kanji Hirai
Journal:  Microbiol Immunol       Date:  2003       Impact factor: 1.955

8.  Expression of SERCA isoform with faster Ca2+ transport properties improves postischemic cardiac function and Ca2+ handling and decreases myocardial infarction.

Authors:  M A Hassan Talukder; Anuradha Kalyanasundaram; Xue Zhao; Li Zuo; Poornima Bhupathy; Gopal J Babu; Arturo J Cardounel; Muthu Periasamy; Jay L Zweier
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-07-13       Impact factor: 4.733

Review 9.  Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury.

Authors:  Elizabeth Murphy; Charles Steenbergen
Journal:  Physiol Rev       Date:  2008-04       Impact factor: 37.312

10.  Constitutive cardiac overexpression of sarcoplasmic/endoplasmic reticulum Ca2+-ATPase delays myocardial failure after myocardial infarction in rats at a cost of increased acute arrhythmias.

Authors:  Ying Chen; Brigitte Escoubet; Fabrice Prunier; Julien Amour; Warner S Simonides; Benoît Vivien; Christophe Lenoir; Michèle Heimburger; Christine Choqueux; Barnabas Gellen; Bruno Riou; Jean-Baptiste Michel; Wolfgang M Franz; Jean-Jacques Mercadier
Journal:  Circulation       Date:  2004-03-22       Impact factor: 29.690

View more
  8 in total

1.  Increased susceptibility to cardiovascular disease in offspring born from dams of advanced maternal age.

Authors:  Christy-Lynn M Cooke; Amin Shah; Raven D Kirschenman; Anita L Quon; Jude S Morton; Alison S Care; Sandra T Davidge
Journal:  J Physiol       Date:  2018-06-21       Impact factor: 5.182

2.  Hepatic HAX-1 inactivation prevents metabolic diseases by enhancing mitochondrial activity and bile salt export.

Authors:  Fawzi Alogaili; Sivaprakasam Chinnarasu; Anja Jaeschke; Evangelia G Kranias; David Y Hui
Journal:  J Biol Chem       Date:  2020-02-20       Impact factor: 5.157

3.  Intrinsically disordered HAX-1 regulates Ca2+ cycling by interacting with lipid membranes and the phospholamban cytoplasmic region.

Authors:  Erik K Larsen; Daniel K Weber; Songlin Wang; Tata Gopinath; Daniel J Blackwell; Michael P Dalton; Seth L Robia; Jiali Gao; Gianluigi Veglia
Journal:  Biochim Biophys Acta Biomembr       Date:  2019-08-07       Impact factor: 3.747

4.  Heat shock protein 47 confers chemoresistance on pancreatic cancer cells by interacting with calreticulin and IRE1α.

Authors:  Akihiro Yoneda; Kenjiro Minomi; Yasuaki Tamura
Journal:  Cancer Sci       Date:  2021-06-09       Impact factor: 6.716

5.  The YAP/SERCA2a signaling pathway protects cardiomyocytes against reperfusion-induced apoptosis.

Authors:  Jiankai Zhong; Haichun Ouyang; Sulin Zheng; Zhongzhou Guo; Yuying Chen; Yuanlin Zhong; Wenhao Zhong; Liuer Zuo; Jianhua Lu
Journal:  Aging (Albany NY)       Date:  2020-07-09       Impact factor: 5.682

Review 6.  Mechanisms underlying pathological Ca2+ handling in diseases of the heart.

Authors:  Satadru K Lahiri; Yuriana Aguilar-Sanchez; Xander H T Wehrens
Journal:  Pflugers Arch       Date:  2021-01-05       Impact factor: 3.657

7.  MicroRNA‑125a‑5p regulates liver cancer cell growth, migration and invasion and EMT by targeting HAX1.

Authors:  Zhongming Zha; Jie Li
Journal:  Int J Mol Med       Date:  2020-09-16       Impact factor: 4.101

Review 8.  The Potential of Hsp90 in Targeting Pathological Pathways in Cardiac Diseases.

Authors:  Richard J Roberts; Logan Hallee; Chi Keung Lam
Journal:  J Pers Med       Date:  2021-12-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.